Navigation Links
Oncothyreon announces issuance of patent for PX-867

BELLEVUE, WA, March 20 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) (TSX: ONY) today announced that the U.S. Patent and Trademark office has issued a patent for PX-867, a small molecule compound currently in preclinical development. The newly issued patent, U.S. Patent # 7,335,679, includes claims covering both composition of matter of PX-867 and pharmaceutical preparations containing PX-867.

PX-867 is an inhibitor of the phosphatidylinositol-3-kinase (PI-3-kinase)/PTEN/Akt pathway, the same pathway targeted by Oncothyreon's small molecule compound PX-866, which is expected to enter clinical development in 2008. Signaling through this pathway plays a critical role in the survival of cancer cells, and also contributes to a number of other disease states, including cardiovascular disease and autoimmune disease. The preclinical development for PX-867 has focused on cardiovascular disease. In particular, the compound has demonstrated activity as a coating on intravascular stents in preclinical models of atherosclerotic disease.

"We intend to seek a partner to develop PX-867 in non-oncology indications, particularly in cardiovascular applications, while focusing our internal development efforts on PX-866 in oncology, our core area of expertise," said Robert L. Kirkman, M.D. President and CEO of Oncothyreon. "We expect to file an Investigational New Drug Application for PX-866 in the coming quarter and to initiate a Phase 1 trial soon thereafter."

About Oncothyreon

Oncothyreon is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Oncothyreon's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients. For more information, visit

Forward Looking Statements

In order to provide Oncothyreon's investors with an understanding of its current intentions and future prospects, this release contains statements that are forward looking, including statements related to filing an IND for PX-866, future clinical development plans for PX-866, and plans to seek a collaboration partner for PX-867. These forward-looking statements represent Oncothyreon's intentions, plans, expectations and beliefs and are based on its management's experience and assessment of historical and future trends and the application of key assumptions relating to future events and circumstances.

Forward-looking statements involve risks and uncertainties, including risks and uncertainties related to Oncothyreon's business and the general economic environment. Many of these risks and uncertainties are beyond Oncothyreon's control. These risks, uncertainties and other factors could cause our actual results to differ materially from those projected in forward-looking statements. Risks, uncertainties, and assumptions include those predicting the timing, duration and results of clinical trials, the timing and results of regulatory reviews, the safety and efficacy of PX-866 and PX-867, and the likelihood of achieving a collaboration agreement for PX-867. There can be no guarantee that the results of preclinical studies will be predictive of either safety or efficacy in future clinical trials. These and other risks and uncertainties are described in the reports and other documents filed by Oncothyreon Inc. with the SEC and/or Canadian regulatory authorities.

Although Oncothyreon believes that any forward-looking statements contained herein are reasonable, it can give no assurance that its expectations are correct. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. For a detailed description of the risks and uncertainties associated with Oncothyreon, you are encouraged to review the official corporate documents filed with the securities regulators in the United States on U.S. EDGAR and in Canada on SEDAR. Oncothyreon is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

SOURCE Oncothyreon Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Oncothyreon to present at upcoming investment conferences
2. Oncothyreon reports full year and fourth quarter 2007 financial results
3. Oncothyreon announces March 10th webcast of fourth quarter and full year financial results conference call
4. Oncothyreons PX-478 is effective in preclinical model of human lung cancer
5. Oncothyreon launches new corporate website
6. Oncothyreon to present at BIO CEO & Investor Conference
7. Oncothyreon highlights corporate and clinical objectives for 2008
8. Biomira announces plan to change name to Oncothyreon
9. 3SBio Inc. Announces Promotion of David Chen as Chief Operating Officer
10. Society for Biomolecular Sciences Announces 2008 Conference Speaker Line-up
11. BioMS Medical Announces 2007 Year End Results
Post Your Comments:
(Date:6/27/2016)... ... ... Parallel 6 , the leading software as a service (SaaS) provider ... Patient Encounter CONSULT module which enables both audio and video telemedicine communication between the ... the CONSULT module, patients and physicians can schedule a face to face virtual patient ...
(Date:6/27/2016)... June 27, 2016  Liquid Biotech ... funding of a Sponsored Research Agreement with The ... cells (CTCs) from cancer patients.  The funding will ... levels correlate with clinical outcomes in cancer patients ... will then be employed to support the design ...
(Date:6/24/2016)... SAN DIEGO , June 24, 2016 /PRNewswire/ ... that more sensitively detects cancers susceptible to PARP ... individual circulating tumor cells (CTCs). The new test ... of HRD-targeted therapeutics in multiple cancer types. ... therapies targeting DNA damage response pathways, including PARP, ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... the release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” ... and retention in this eBook by providing practical tips, tools, and strategies for ...
Breaking Biology Technology:
(Date:5/12/2016)... -- , a brand of Troubadour Research ... the Q1 wave of its quarterly wearables survey. A ... to a program where they would receive discounts for ... "We were surprised to see that so ... , CEO of Troubadour Research, "primarily because there are ...
(Date:4/26/2016)... and LONDON , ... Finacle, part of EdgeVerve Systems, a product subsidiary ... Onegini today announced a partnership to integrate the ...      (Logo: ) ... provide their customers enhanced security to access and ...
(Date:4/14/2016)... 14, 2016 BioCatch ™, ... today announced the appointment of Eyal Goldwerger ... Goldwerger,s leadership appointment comes at a time ... the deployment of its platform at several of the ... which discerns unique cognitive and physiological factors, is a ...
Breaking Biology News(10 mins):